CorMedix Reports 72% Reduction in Bloodstream Infections with DefenCath in Real-World Study
核心洞察
CorMedix announced interim results from an ongoing real-world evidence study showing DefenCath achieved a 72% reduction in catheter-related bloodstream infections (搜索) and 70% reduction in related hospitalizations compared to historical controls.
The study analyzed approximately 7,000 patients receiving DefenCath through September 2025, with over 3,000 patients per month currently receiving the treatment at U.S. Renal Care (搜索) facilities.
DefenCath represents significant cost savings potential, as CMS spends over $3 billion annually on CRBSI-related costs in ESRD patients, with each hospitalization costing approximately $63,000 to $110,000.
CorMedix Therapeutics (搜索) has announced compelling interim results from its ongoing real-world evidence study of DefenCath, demonstrating a 72% reduction in catheter-related bloodstream infections (搜索) (CRBSI) and a 70% reduction in hospitalizations secondary to these infections compared to historical controls. The study, conducted in partnership with U.S. Renal Care (搜索) (USRC), analyzed data from approximately 7,000 patients who received at least one dose of DefenCath through September 2025.
Significant Clinical Impact in Vulnerable Population
DefenCath (taurolidine and heparin) represents the first and only FDA-approved antimicrobial catheter lock solution in the United States, specifically indicated to reduce CRBSI incidence in adult patients with kidney failure (搜索) receiving chronic hemodialysis through central venous catheters. The real-world study commenced upon DefenCath's outpatient commercial launch in July 2024 and is designed to evaluate infection rates and hospitalizations over two years.
Currently, more than 3,000 patients per month receive DefenCath on a routine basis at USRC facilities. Joseph Todisco, CEO of CorMedix, stated, "We are proud to announce interim results for our ongoing real-world evidence study with our partners at USRC. As one of our earliest outpatient customers, they have undertaken a significant effort in working with us on this important long-term study and ensuring patient access to DefenCath to prevent CRBSIs in hemodialysis patients at risk."
Substantial Healthcare Cost Implications
The clinical benefits translate into significant economic impact for the healthcare system. CMS spends more than $3 billion per year on costs associated with CRBSI in the end-stage renal disease (搜索) (ESRD) patient population, with the average CRBSI-related hospitalization estimated to cost approximately $63,000, and up to $110,000 per incident when accounting for other sequelae.
Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer and Senior Vice President of Clinical Research and Medical Affairs at U.S. Renal Care (搜索), commented that "Our organization is deeply committed to advancing innovative therapies for our patients, and we are encouraged by the reduction in both serious infections and hospitalizations demonstrated in these preliminary results."
Patient Advocacy Support
Paul T. Conway, Vice President and Chair of Policy for the American Association of Kidney Patients (AAKP) and a 48-year kidney patient, emphasized the clinical significance: "Every kidney patient receiving hemodialysis understands the inherent and serious risks posed by catheter-related bloodstream infections (搜索), including repeat hospitalizations, exposure to powerful IV antibiotics, jeopardization of their transplant readiness and increased mortality."
Conway added that AAKP "welcomes this new and compelling information about DefenCath and the opportunity to better protect highly vulnerable dialysis patients while simultaneously reducing infection incidents and hospital admissions."
Strong Financial Performance and Future Outlook
CorMedix reported preliminary fourth-quarter 2025 net revenues of approximately $127 million and full-year 2025 revenues of $310 million. The company expects adjusted EBITDA in the range of $77-81 million for Q4 2025. Pro forma net revenues for full-year 2025 were around $400 million, reflecting the impact of the $300 million acquisition of Melinta Therapeutics (搜索).
For 2026, CorMedix projects total revenues of $300-320 million, including $150-170 million from DefenCath specifically. The company anticipates adjusted EBITDA of $100-125 million for full-year 2026. DefenCath's 2026 revenue guidance is weighted toward the first half of the year and assumes modest growth in usage, which the company expects will partially offset price declines throughout 2026.
Competitive Landscape and Market Position
DefenCath currently holds a unique market position as the only FDA-approved therapy for CRBSI prevention, supported by patent protection through 2033. However, the company faces potential competition from established players in the heparin market, including Pfizer, Amphastar Pharmaceuticals, B. Braun, Baxter, and Fresenius Kabi USA, who already market heparin for multiple indications.
The real-world evidence study continues to evaluate secondary endpoints including missed treatment sessions, antibiotic utilization, and tissue plasminogen activator (tPA) utilization. CorMedix believes these data further underscore the LOCK-IT 100 clinical study results on which FDA approval was based and plans to use this evidence in discussions with customers and payers, including Medicare Advantage plans, to establish long-term reimbursement and broaden access.